The DSUR: One Annual Safety Report for an Investigational Medicine, Done Properly

The Development Safety Update Report (DSUR) is the annual safety review that sponsors prepare while a medicine is still in development. Under ICH E2F it is meant to be one harmonised document, but it is often written late, assembled from fragments and read by nobody until an inspector asks for it.

What a DSUR is for

ICH E2F describes the DSUR as a single annual report on the safety of an investigational drug or biological, whether or not it has a marketing authorisation. Its purpose is a periodic, critical look at the safety information gathered during the reporting period: is the emerging profile consistent with what was known, and has anything changed the overall benefit-risk picture for the studied populations?

It is not a collection of line listings. The guideline expects an integrated assessment, with the listings and tabulations in support.

Timing and scope

  • One report per active substance, covering all indications, dosage forms, strengths and populations under study, rather than one report per trial.
  • Annual cycle, anchored to the Development International Birth Date, which is the date of the first authorisation to conduct a clinical trial anywhere in the world. The data lock point follows from it.
  • Submission within 60 calendar days of the data lock point, as set out in ICH E2F.
  • Reference safety information is normally the Investigator’s Brochure, which means the DSUR and the IB must tell a consistent story.

How it fits with EU clinical trial law

Under Regulation (EU) No 536/2014, Article 43, the sponsor submits an annual safety report on each investigational medicinal product to the Agency through the electronic system, containing aggregate and anonymised data. Member State authorities describe the DSUR format as the basis for that report, and a simplified version is available in limited circumstances for non-commercial sponsors. Sponsors should check the current EMA and national guidance for the exact route and any simplified option before they plan a submission.

Where DSURs go wrong

  • Starting after the data lock point, with no agreed data cut and no named authors.
  • Treating the DSUR as a copy of the IB or of a PSUR, when the focus and audience are different.
  • Inconsistent exposure estimates and case counts between the DSUR, the safety database and the IB.
  • A weak overall safety assessment that lists events but never says whether the benefit-risk balance has shifted.
  • Unclear ownership when the sponsor, a licensee and a CRO each hold part of the data.

A practical way to prepare

Fix the data lock point and the report calendar at the start of development, assign reconciliation of safety and clinical databases early, and agree who signs off the benefit-risk statement. Where a product later gains an authorisation, plan the hand-over from DSUR to PSUR or PBRER cycles so that no reporting period is left uncovered.

How PQRA helps

PQRA can plan the DSUR calendar for a development programme, support authoring and review, check consistency with the Investigator’s Brochure and the safety database, and advise on how submission works under the Clinical Trials Regulation. We can also review an existing DSUR process for gaps before an inspection.

Contact PQRA to discuss your development safety reporting.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *